Outcomes of pancreatectomy for histologically proven intraductal papillary mucinous neoplasm with reference to Fukuoka guidelines

被引:0
|
作者
Lee, Kit Fai [1 ]
Lo, Eugene Y. J. [1 ]
Lok, Hon Ting [1 ]
Fung, Andrew K. Y. [1 ]
Kung, Janet K. C. [1 ]
Chong, Charing C. N. [1 ]
Wong, John [1 ]
Lai, Paul B. S. [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Hepatobiliary & Pancreat Surg, Hong Kong, Peoples R China
关键词
Fukuoka guidelines; high-grade dysplasia; intraductal papillary neoplasm; IPMN; pancreatic resection; CONSENSUS GUIDELINES; PANCREAS; MANAGEMENT; DIAGNOSIS; DYSPLASIA; NOMOGRAM; IPMN;
D O I
10.1111/ans.19303
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundIntraductal papillary mucinous tumour (IPMN) of pancreas is increasingly recognized to have malignant potential. Fukuoka guidelines are commonly used to select patients with IPMN for resection due to high chance of malignancy, which includes high-grade dysplasia (HGD) or invasive carcinoma (IC).MethodsA retrospective study on consecutive patients who have undergone pancreatectomy with IPMN as the final pathology was performed. Operative and survival outcomes were analysed. The positive predictive values (PPV) of high-risk stigmata (HRS) and worrisome features (WF) of Fukuoka guidelines for HGD/IC were determined.ResultsBetween August 2011 and September 2020, various types of pancreatectomy were performed for 36 patients with histologically proven IPMN. They included 26 pancreaticoduodenectomy, 7 distal pancreatectomy, 2 central pancreatectomy, and 1 total pancreatectomy. There were 30 branch duct type IPMN, 5 main duct type, and 1 mixed type. There was no 30-day mortality. Overall complications and pancreatic fistula occurred in 44.4% and 5.6% of patients, respectively. Patients without HGD/IC had 100% survival at 5 years with no recurrent disease. There were 13 patients with HGD/IC, their 1-, 3-, 5-year overall and disease-free survival were 84.6%, 76.9%, 67.3% and 84.6%, 68.4%, 58.6%, respectively, both significantly shorter than non-HGD/IC group (P = 0.002 and 0.001, respectively). The PPV of HRS and WF for HGD/IC were 33.3% and 23.5%, respectively. The combined PPV of HRS and WF for HGD/IC was 38.0%.ConclusionSurvival after pancreatectomy for IPMN was favourable, but was significantly worse in the presence of HGD/IC. Fukuoka guidelines were useful in predicting malignant IPMN.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Medial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm: Report of 2 Cases
    Sawa, Y.
    Hata, S.
    Yamaguchi, H.
    Teruya, M.
    Kaminishi, M.
    PANCREAS, 2019, 48 (10) : 1517 - 1517
  • [2] Spleen-preserving distal pancreatectomy for intraductal papillary mucinous neoplasm
    Sakamoto, Katsunori
    GLAND SURGERY, 2024, 13 (09) : 1665 - 1669
  • [3] Long-term outcomes of patients with multifocal intraductal papillary mucinous neoplasm following pancreatectomy
    Hashimoto, Daisuke
    Satoi, Sohei
    Yamamoto, Tomohisa
    Yamaki, So
    Ishida, Mitsuaki
    Hirooka, Satoshi
    Shibata, Nobuhiro
    Boku, Shogen
    Ikeura, Tsukasa
    Sekimoto, Mitsugu
    PANCREATOLOGY, 2022, 22 (07) : 1046 - 1053
  • [4] Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm
    Cauley, Christy E.
    Waters, Joshua A.
    Dumas, Ryan P.
    Meyer, Juliana E.
    Al-Haddad, Mohammad A.
    DeWitt, John M.
    Lillemoe, Keith D.
    Schmidt, C. Max
    JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 16 (02) : 258 - 265
  • [5] Intraductal Papillary Mucinous Neoplasm
    Reis, Joseph, III
    Schiffman, Scott
    Voci, Susan
    ULTRASOUND QUARTERLY, 2012, 28 (02) : 133 - 135
  • [6] Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm
    Cauley, Christy E.
    Waters, Joshua A.
    Dumas, Ryan P.
    Meyer, Juliana E.
    Al-Haddad, Mohammad A.
    DeWitt, John M.
    Lillemoe, Keith D.
    Schmidt, C. Max
    GASTROENTEROLOGY, 2011, 140 (05) : S1008 - S1008
  • [7] Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm
    Christy E. Cauley
    Joshua A. Waters
    Ryan P. Dumas
    Juliana E. Meyer
    Mohammad A. Al-Haddad
    John M. DeWitt
    Keith D. Lillemoe
    C. Max Schmidt
    Journal of Gastrointestinal Surgery, 2012, 16 : 258 - 266
  • [8] Intraductal papillary mucinous neoplasm
    Shi, Chanjuan
    Hruban, Ralph H.
    HUMAN PATHOLOGY, 2012, 43 (01) : 1 - 16
  • [9] Intraductal papillary mucinous neoplasm
    Ramia Angel, Jose Manuel
    de la Plaza Llamas, Roberto
    Dolores Sanchez-Tembleque, Maria
    Perez Mies, Belen
    Garcia-Parreno Jofre, Jorge
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2011, 103 (09) : 480 - 481
  • [10] Intraductal papillary mucinous neoplasm
    Suresh T. Chari
    Current Treatment Options in Gastroenterology, 2002, 5 (5) : 339 - 344